GSK BHR Study (Sont - Second Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
Asthma
Interventions
DRUG

Placebo

Twice daily dosing

DRUG

Placebo

Twice daily dosing

DRUG

FP 100mcg

Twice daily dosing

DRUG

FP 250mcg

Twice daily dosing

DRUG

FP 500mcg

Twice daily dosing

DRUG

FSC 100/50mcg

Twice daily dosing

DRUG

FSC 250/50mcg

Twice daily dosing

DRUG

FSC500/50mcg

Twice daily dosing

Trial Locations (57)

9010

GSK Investigational Site, Varna

11501

GSK Investigational Site, Mineola

19013

GSK Investigational Site, Upland

21236

GSK Investigational Site, Baltimore

23229

GSK Investigational Site, Richmond

24541

GSK Investigational Site, Danville

27103

GSK Investigational Site, Winston-Salem

28207

GSK Investigational Site, Charlotte

28401

GSK Investigational Site, Wilmington

29303

GSK Investigational Site, Spartanburg

32207

GSK Investigational Site, Jacksonville

32750

GSK Investigational Site, Longwood

33180

GSK Investigational Site, Aventura

33609

GSK Investigational Site, Tampa

33613

GSK Investigational Site, Tampa

35501

GSK Investigational Site, Jasper

37922

GSK Investigational Site, Knoxville

44195

GSK Investigational Site, Cleveland

45231

GSK Investigational Site, Cincinnati

46617

GSK Investigational Site, South Bend

48152

GSK Investigational Site, Livonia

53792

GSK Investigational Site, Madison

60523

GSK Investigational Site, Oak Brook

63017

GSK Investigational Site, Chesterfield

68131

GSK Investigational Site, Omaha

75231

GSK Investigational Site, Dallas

77030

GSK Investigational Site, Houston

77546

GSK Investigational Site, Friendswood

80033

GSK Investigational Site, Wheat Ridge

80112

GSK Investigational Site, Englewood

80230

GSK Investigational Site, Denver

80526

GSK Investigational Site, Fort Collins

81008

GSK Investigational Site, Pueblo

83814

GSK Investigational Site, Coeur d'Alene

85304

GSK Investigational Site, Glendale

85724

GSK Investigational Site, Tucson

90025

GSK Investigational Site, Los Angeles

90048

GSK Investigational Site, Los Angeles

90806

GSK Investigational Site, Long Beach

92647

GSK Investigational Site, Huntington Beach

97035

GSK Investigational Site, Lake Oswego

97401

GSK Investigational Site, Eugene

98105

GSK Investigational Site, Seattle

98226

GSK Investigational Site, Bellingham

88040970

GSK Investigational Site, Florianópolis

35294-0012

GSK Investigational Site, Birmingham

90095-1752

GSK Investigational Site, Los Angeles

50309-1426

GSK Investigational Site, Des Moines

02747

GSK Investigational Site, North Dartmouth

68198-2456

GSK Investigational Site, Omaha

43614-5809

GSK Investigational Site, Toledo

75231-4307

GSK Investigational Site, Dallas

53209-0996

GSK Investigational Site, Milwaukee

21941-590

GSK Investigational Site, Rio de Janeiro

Unknown

GSK Investigational Site, São Paulo

1431/1000

GSK Investigational Site, Sofia

00921

GSK Investigational Site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01324362 - GSK BHR Study (Sont - Second Study) | Biotech Hunter | Biotech Hunter